OCEA (Ocean Biomedical) Median PS Value: $0.00 (As of Jun. 29, 2026)


What is Ocean Biomedical Median PS Value?

Ocean Biomedical OCEA -75.00% Median PS Value is $0.00 as of Jun. 29, 2026.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Ocean Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0. Ocean Biomedical's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2026-06-29), Ocean Biomedical's share price is $0.0001. Ocean Biomedical's Median PS Value is $0.00. Therefore, Ocean Biomedical's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Ocean Biomedical's Median PS Value or its related term are showing as below:

OCEA's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Ocean Biomedical  (OTCPK:OCEA) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Ocean Biomedical's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocean Biomedical Median PS Value Related Terms


Ocean Biomedical Median PS Value Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical Median PS Value Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Median PS Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OCEA vs SIGY, ENDV, SCPX: Median PS Value Comparison

For the Biotechnology subindustry, Ocean Biomedical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocean Biomedical Price-to-Median-PS-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's Price-to-Median-PS-Value falls into.



Ocean Biomedical Median PS Value Calculation

Ocean Biomedical's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Ocean Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of $0.00 mean?
Ocean Biomedical (OCEA) has a Median PS Value of $0.00 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ocean Biomedical and its competitors.
Is Ocean Biomedical's Median PS Value too high?
Ocean Biomedical's current Median PS Value is $0.00.
How does Ocean Biomedical's Median PS Value compare to SIGY and ENDV?
Ocean Biomedical's Median PS Value of $0.00 can be compared against companies in the Biotechnology industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ocean Biomedical and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocean Biomedical's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current Median PS Value is $0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.